Clinicians from the Mayo Clinic, Phoenix, AZ, USA, have shown that holmium laser enucleation of the prostate (HoLEP) is a safe and effective therapy for BPH, regardless of age. In a retrospective review of all patients with lower urinary tract symptoms (LUTS) resulting from prostate enlargement who were treated with HoLEP at their clinic over a 4-year period, Chinedu and colleagues found that overall morbidity, hospital stay, and 1-year functional outcomes were similar for patients aged 50-59 years (? = 22), 60-69 years (n = 91), 70-79 years (? = 153), and >80 years (n = 45). Although anticoagulation medication use and mean enucleated prostate weight were significantly greater in the older cohorts, there were no differences between the groups in terms of mean haemoglobin change, length of hospital stay (1.18-1.68 days), or PSA reduction at 6 months. Patients aged >80 years were more likely to need a blood transfusion after surgery and morcellation time was slightly longer in the older groups, but these effects did not reach statistical significance.
展开▼
